reuters.com
23-May-2008
By Diane Bartz WASHINGTON, May 23 (Reuters) - Brand name pharmaceutical companies struck 14 deals that led to delayed sale of cheaper generic drugs in the 2007 fiscal year, the U.S. Federal Trade Commission said. The FTC considers the controversial deals a violation of antitrust law but the...
[read full story]